<DOC>
	<DOC>NCT01740609</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.</brief_summary>
	<brief_title>A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Male subjects and female of nonchildbearing potential subjects between the ages of 18 and 55. BMI between 18.5 to 32 kg/m2. Total body weight ≥40 kg and ≤120 kg. Previous treatment with an antibody within 6 months prior to Day 1. Pregnant or nursing females; females of childbearing potential. History of sensitivity to heparin or heparininduced thrombocytopenia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>RN168</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>